DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Menu 返回 ICH-Subscription

ICH On-Demand Subscription

Don’t miss out on the latest ICH sessions from DIA conferences around the world.

The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug development, manufacturing, and registration.

Throughout the year, new recordings will be added as they become available. Purchase a one-year subscription to get access to this library of dynamic, on-demand content. Get the information you need anywhere, anytime, on any device.

Current Recordings Include

  • E6 and E8 Renovation Plan of Action
  • Understanding ICH E6(R2) and the Impact to Clinical Trial Documentation and the Trial Master File
  • E9(R1) Estimands
  • E11 Pediatric Guideline Suite
  • ICH Q12: Solutions to Facilitate Post-Approval Change Management Throughout a Product’s Lifecycle
  • E17 Multi-Regional Clinical Trials
  • E19 Optimizing Safety Data Collection
  • Has the ICH Reform Been a Success?
  • Overview of the Current ICH
  • And More!


  • Related eLearning Products

    Clinical Trial Management Comprehensive eLearning Bundle

    This eLearning bundle includes the Clinical Trial Fundamentals eLearning Program and the Informed Consent: Comprehensive Concepts and Components eLearning Module.

    Informed Consent: Comprehensive Concepts and Components eLearning Module

    This comprehensive module provides the key concepts of informed consent. It explains the components of a complete and appropriate consent form as specified by the International Council on Harmonisation (ICH) and the US FDA, as well as guidance for the creation and appropriate wording of these components. It also includes a discussion on the benefits and concerns with electronic informed consent, and presents publications and projects that explore the use of eConsent.

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。